Skip to main content
. Author manuscript; available in PMC: 2012 Jun 13.
Published in final edited form as: Int J Cancer. 2011 Aug 3;130(8):1733–1744. doi: 10.1002/ijc.26164

Figure 1.

Figure 1

(a) Expression of IL-8 mRNA in human bronchial epithelial cell lines (noncancerous cells; N = 3), SCLC cell lines (N = 22), NSCLC cell lines with wild-type KRAS/EGFR (KRAS/EGFR WT; N = 10), NSCLC cell lines harboring EGFR mutations (EGFR mutant; N = 10) or KRAS mutations (KRAS mutant; N = 10). IL-8 levels were significantly higher in KRAS mutant (p < 0.01) or EGFR mutant (p < 0.05) than in KRAS/EGFR WT. (b) IL-8 protein concentration in cultured lung cancer cell lines as determined by ELISA assay. Twenty-four hours after plating 106 cells on 100 mm dishes, culture medium was replaced with 10 ml of RPMI 1640 medium with 5% serum. After cells were cultured for additional 48 hr, medium was collected, and an ELISA assay was performed. IL-8 levels were significantly higher in EGFR Mutant (p < 0.05) or KRAS Mutant (p < 0.01) NSCLCs than in KRAS/EGFR WT. Expressions of (c) CXCR1 and (d) CXCR2 mRNA in the noncancerous and NSCLC cell lines. The arbitrary units (a.u.) of the expressions of IL-8, CXCR1, and CXCR2 were calculated as described in Materials and Methods. Points represent the mean IL-8 levels from three independent experiments. Lines represent the median levels in each group. Differences were analyzed by Kruskal–Wallis test with Dunn’s multiple comparisons.